1. Home
  2. COGT

COGT

Cogent Biosciences Inc.

Logo Cogent Biosciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Founded: 2014 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 659.7M IPO Year: 2018
Target Price: $16.25 AVG Volume (30 days): 2.2M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.42 EPS Growth: N/A
52 Week Low/High: $3.67 - $13.50 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: